Cryoport's MVE Biological Solutions Introduces Next Generation Vapor Shippers
Rhea-AI Summary
Cryoport (NASDAQ:CYRX) has announced the launch of its next-generation vapor shippers, the SC 4/2V and SC 4/3V, through its MVE Biological Solutions division. The new models feature significant improvements in hold times, with the SC 4/2V extending from 13 to 19 days and the SC 4/3V from 21 to 26 days.
The enhanced vapor shippers incorporate several innovative features, including the patented BEND DON'T BREAK™ technology for impact absorption, an integrated lid locking tab, and patent-pending Vapor Shield Technology to prevent vacuum loss. These improvements are designed to provide better protection for sensitive biological materials during transportation, including cells, tissues, vaccines, and reproductive health materials.
Positive
- Extended hold times: SC 4/2V increased to 19 days (from 13) and SC 4/3V to 26 days (from 21)
- New BEND DON'T BREAK™ technology reduces damage risk during shipping
- Enhanced safety features including Vapor Shield Technology and integrated lid locking
- Reduced operating costs through lower refill frequency
Negative
- None.
Insights
Cryoport's upgraded vapor shippers offer extended hold times and enhanced protection features, strengthening their specialized cryogenic transport capabilities.
The launch of MVE Biological Solutions' next-generation SC 4/2V and SC 4/3V vapor shippers represents a meaningful evolutionary improvement in Cryoport's cryogenic transport technology. The most significant advancement is the substantially extended hold times—up to 19 days for the SC 4/2V (a
These extended hold times directly address a critical pain point in temperature-sensitive biological material transportation: transit delays. The longer a sample can remain at proper cryogenic temperatures without intervention, the lower the risk of compromised integrity during shipping disruptions.
The incorporation of MVE's patented BEND DON'T BREAK™ technology adds crucial physical protection through impact-absorbing design. This addresses another common failure point—physical damage during transport—which can be catastrophic for irreplaceable biological materials. The additional features like the integrated lid locking tab and Vapor Shield Technology further demonstrate a comprehensive approach to risk mitigation in the cold chain.
For context, these improvements matter significantly in high-value shipments of cell therapies, reproductive materials, and specialized pharmaceuticals where a single temperature excursion can render extremely valuable materials unusable. By extending hold times and enhancing physical protection, Cryoport is reducing one of the most significant operational risks in advanced biological logistics—temperature excursions that lead to product loss.
New SC vapor shipper series improves reliability through extended hold times and patented impact-absorbing and Vapor Shield Technology
Built on MVE's legacy SC 4/2V and 4/3V vapor shipper platform, the next-generation SC 4/2V and 4/3V models have been redesigned utilizing innovative technologies to offer customers added protection during extended or challenging shipments. These four-liter vapor shippers are engineered to safely transport critical biological materials such as cells and tissues materials for cell therapies, biopharma, reproductive health materials, and animal health materials, including vaccines, while maintaining the materials' integrity throughout the journey.
The new SC 4/2V and SC 4/3V vapor shipper models include several key advancements designed to enhance performance and reliability. Hold times for both next-generation models have been significantly extended to up to 19 days for the SC 4/2V (previously 13 days) and 26 days for the SC 4/3V (up from 21 days) which provides greater flexibility and security during transit delays. MVE's patented BEND DON'T BREAK™ technology features a specially designed top that flexes under stress, absorbing impact to reduce the risk of damage during rough handling that sometimes happens during shipping.
"At MVE, we are committed to continuously refining our products to meet the evolving demands of our customers," said Mike Duich, President and CEO of MVE Biological Solutions. "The new SC 4/2V and 4/3V vapor shippers, built on our proven and trusted platform, are now strengthened with longer hold times, reduced refill frequency and lower operating costs. Additional features of our patent-pending technology also protect against vacuum degradation and absorbs shocks, with the ultimate goal of reducing damage-related failures and costly re-shipments. These enhancements reflect our broader mission to support scientific progress with robust, dependable, and cost-efficient cryogenic systems."
Jerrell Shelton, CEO of Cryoport added, "these advances in the SC series of our patented vapor shippers are a part of our ongoing efforts to continually improve our products and services that support our advanced temperature-controlled supply chain solutions for the life sciences. By providing longer temperature hold times, better protection against sudden shock along with additional security features, we have further reduced the supply chain risks for highly valued temperature sensitive life sciences materials which helps with the advancement of the life sciences industry."
Other upgraded features of the new vapor shippers include a newly integrated lid locking tab which helps prevent breakage, along with MVE's patent-pending Vapor Shield Technology, which minimizes the risk of vacuum loss caused by liquid nitrogen overfilling. These enhancements work together to provide greater reliability and "peace of mind" when transporting critical biological materials.
For more information on the SC 4/2V and SC 4/3V vapor shippers, please visit https://mvebio.com/.
About Cryoport, Inc
Cryoport, Inc. (Nasdaq: CYRX), is a global leader in temperature-controlled supply chain solutions for the Life Sciences, with an emphasis on regenerative medicine. We support biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers with a comprehensive suite of services and products designed to minimize risk and maximize reliability across the temperature-controlled supply chain for the Life Sciences. Our integrated supply chain platform includes the Cryoportal® Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized biologistics, biostorage, bioservices, and cryogenic systems, which in varying combinations deliver end-to-end solutions that meet the rigorous demands of the life sciences. With innovation, regulatory compliance, and agility at our core, we are "Enabling the Future of Medicine™."
Our corporate headquarters, located in
For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at www.x.com/cryoport for live updates.
Forward-Looking Statements
Statements in this press release which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to MVE Biological Solutions' SC 4/2V and SC 4/3V shippers, including their potential impact on future revenue and revenue streams. It is important to note that Cryoport's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in Cryoport's cash flow, market acceptance risks, and technical development risks. Cryoport's business could be affected by other factors discussed in Cryoport's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and Cryoport cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, Cryoport disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cryoports-mve-biological-solutions-introduces-next-generation-vapor-shippers-302499501.html
SOURCE Cryoport, Inc.
FAQ
What are the new features of Cryoport's SC 4/2V and SC 4/3V vapor shippers?
How long can Cryoport's new SC 4/3V vapor shipper maintain temperature?
What types of materials can be transported in Cryoport's new vapor shippers?
How does Cryoport's BEND DON'T BREAK technology work?
What is the capacity of Cryoport's new vapor shippers?
